Evidence map›Paper›PMID 42828389›Full record

ArticleACS pharmacology & translational science2026

Antiproliferation and Anti-invasion Activity of Binuclear Copper(II) Complex in BRAFi-Resistant Melanoma Cells.

Manoel Oliveira de Moraes Junior, Larissa Anastácio da Costa Carvalho, Yasmin Catherine da Paz Mendonça, Renaira Oliveira da Silva, Cleia Justino Nunes, Keli Lima, João Agostinho Machado-Neto, Tiago Rodrigues, Vito Rebecca, Corine Bertolotto and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Manoel Oliveira de Moraes JuniorDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.ORCID https://orcid.org/0000-0001-6354-1064
Larissa Anastácio da Costa CarvalhoDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
Yasmin Catherine da Paz MendonçaDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
Renaira Oliveira da SilvaDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
Cleia Justino NunesDepartment of Fundamental Chemistry, Chemistry Institute, University of São Paulo, São Paulo, SP 05508-000, Brazil.
Keli LimaDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
João Agostinho Machado-NetoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.ORCID https://orcid.org/0000-0002-2937-8109
Tiago RodriguesCenter for Natural and Human Sciences, Federal University of ABC, Santo André, SP 09210-580, Brazil.ORCID https://orcid.org/0000-0003-1277-0224
Vito RebeccaDepartment of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, United States.
Corine BertolottoCentre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice 06204, France.
Ana Maria da Costa FerreiraDepartment of Fundamental Chemistry, Chemistry Institute, University of São Paulo, São Paulo, SP 05508-000, Brazil.ORCID https://orcid.org/0000-0001-9898-1692
Silvya Stuchi Maria-EnglerDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma lethality is driven by high intratumoral heterogeneity, metastatic competence, and phenotypic plasticity, which foster rapid emergence of resistance to targeted therapies such as BRAF inhibitors (BRAFi, e.g. vemurafenib). Copper-(II) complexes have emerged as promising anticancer candidates, yet their activity against BRAFi-resistant melanoma remains poorly defined. Here, we show that the binuclear copper-(II) complex [Cu

Indexed as

BRAFi-resistancecell death mechanismscopper(II) complexesmelanoma

Identifiers

PMID42828389
PMCPMC13632889

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.